Fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin. Issue 6 (8th April 2019)

• Record Type: Journal Article
• Authors: Vilsbøll, Tina; Blevins, Thomas C.; Jodar, Esteban; Poulter, Neil; Tentolouris, Nikolaos; Ross Agner, Bue F.; Lehmann, Lucine; Leiter, Lawrence A.
• Is Part Of: Diabetes, obesity & metabolism. Volume 21:Issue 6(2019)
• Page Start: 1506
• Page End: 1512
• Publication Date: 2019-04-08
• Subjects: basal insulin -- cardiovascular disease -- liraglutide -- type 2 diabetes; Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.13675
• Languages: English
• ISSNs: 1462-8902

Abstract

Abstract : In this post hoc analysis we investigated the effects of insulin degludec/liraglutide fixed‐ratio combination (IDegLira) versus comparators on cardiovascular (CV) risk markers in participants in the DUAL II (vs. insulin degludec), DUAL V (vs. insulin glargine 100 units/mL) and DUAL VII (vs. basal–bolus therapy) trials, grouped by sex, age (<65 years, ≥65 years) and diabetes duration (<10 years, ≥10 years). Treatment contrasts were in favour of IDegLira in many subgroups for changes from baseline in glycated haemoblogin (DUAL II, DUAL V), body weight (all three trials), systolic blood pressure (BP; all three trials), HDL cholesterol (DUAL VII) and LDL cholesterol (DUAL II, DUAL V). Higher heart rates were seen with IDegLira versus comparators (all three trials) plus significantly higher diastolic BP in men (DUAL V). Differences in treatment effect were seen between sexes in waist circumference (DUAL II), systolic BP (DUAL II, DUAL V) and triglycerides (DUAL VII), and between diabetes durations in LDL cholesterol (DUAL V). In conclusion, IDegLira is associated with a general improvement in CV risk markers compared with basal insulin or basal–bolus therapy after 26 weeks of treatment.